(Il Sole 24 Ore Radiocor) – New York, May 05 – In the first three months of the year, Pfizer saw its 15% profits fall, in the wake of the drop in turnover in two key divisions, the pharmaceutical one (-13% to 5.99 billion dollars) and innovation (-7% to 3.08 billion dollars). The pharmaceutical giant posted earnings of $2.33 billion, 36 cents a share, versus $2.75 billion, 38 cents a share, in the same period last year. Excluding special items, profits rose 51 cents a share to 57 cents. Turnover dropped by 8.5% to 11.35 billion dollars, excluding extraordinary charges -9% to 11.3 billion. Analysts were expecting profits of 55 cents a share on $12.08 billion in business.
